Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.25
COO's Cash to Debt is ranked higher than
53% of the 308 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. COO: 0.25 )
COO' s 10-Year Cash to Debt Range
Min: 0   Max: 1.92
Current: 0.25

0
1.92
Equity to Asset 0.79
COO's Equity to Asset is ranked higher than
88% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. COO: 0.79 )
COO' s 10-Year Equity to Asset Range
Min: -0.06   Max: 0.8
Current: 0.79

-0.06
0.8
Interest Coverage 33.37
COO's Interest Coverage is ranked higher than
73% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.96 vs. COO: 33.37 )
COO' s 10-Year Interest Coverage Range
Min: 1.07   Max: 33.37
Current: 33.37

1.07
33.37
F-Score: 6
Z-Score: 8.42
M-Score: -2.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 19.27
COO's Operating margin (%) is ranked higher than
90% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.30 vs. COO: 19.27 )
COO' s 10-Year Operating margin (%) Range
Min: 4.82   Max: 23.82
Current: 19.27

4.82
23.82
Net-margin (%) 18.65
COO's Net-margin (%) is ranked higher than
92% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.08 vs. COO: 18.65 )
COO' s 10-Year Net-margin (%) Range
Min: -1.18   Max: 34.8
Current: 18.65

-1.18
34.8
ROE (%) 12.32
COO's ROE (%) is ranked higher than
83% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. COO: 12.32 )
COO' s 10-Year ROE (%) Range
Min: -0.77   Max: 108.5
Current: 12.32

-0.77
108.5
ROA (%) 9.44
COO's ROA (%) is ranked higher than
88% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. COO: 9.44 )
COO' s 10-Year ROA (%) Range
Min: -0.43   Max: 18.11
Current: 9.44

-0.43
18.11
ROC (Joel Greenblatt) (%) 27.04
COO's ROC (Joel Greenblatt) (%) is ranked higher than
81% of the 298 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.70 vs. COO: 27.04 )
COO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 5.22   Max: 52.76
Current: 27.04

5.22
52.76
Revenue Growth (%) 8.70
COO's Revenue Growth (%) is ranked higher than
79% of the 276 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. COO: 8.70 )
COO' s 10-Year Revenue Growth (%) Range
Min: 4.8   Max: 27.8
Current: 8.7

4.8
27.8
EBITDA Growth (%) 5.60
COO's EBITDA Growth (%) is ranked higher than
70% of the 231 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.10 vs. COO: 5.60 )
COO' s 10-Year EBITDA Growth (%) Range
Min: -8.6   Max: 63.4
Current: 5.6

-8.6
63.4
EPS Growth (%) 34.90
COO's EPS Growth (%) is ranked higher than
92% of the 237 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. COO: 34.90 )
COO' s 10-Year EPS Growth (%) Range
Min: -18   Max: 474.9
Current: 34.9

-18
474.9
» COO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

COO Guru Trades in Q3 2013

Chuck Royce 500 sh (New)
RS Investment Management 177,735 sh (+117.05%)
Jim Simons 31,600 sh (+93.87%)
Paul Tudor Jones 4,200 sh (+50%)
Ken Fisher 62,650 sh (+9.43%)
Manning & Napier Advisors, Inc Sold Out
Caxton Associates Sold Out
Mario Gabelli 34,500 sh (-9.21%)
Steven Cohen 3,218 sh (-91.29%)
» More
Q4 2013

COO Guru Trades in Q4 2013

Bill Frels 3,000 sh (New)
Chuck Royce 3,800 sh (+660%)
Steven Cohen 15,338 sh (+376.63%)
Jim Simons 129,498 sh (+309.8%)
RS Investment Management Sold Out
Mario Gabelli 30,500 sh (-11.59%)
Ken Fisher 53,850 sh (-14.05%)
Paul Tudor Jones 3,406 sh (-18.9%)
» More
Q1 2014

COO Guru Trades in Q1 2014

Ron Baron 245,624 sh (New)
Manning & Napier Advisors, Inc 97,210 sh (New)
Steven Cohen 115,186 sh (+650.98%)
Paul Tudor Jones 5,907 sh (+73.43%)
Chuck Royce 3,800 sh (unchged)
Bill Frels Sold Out
Jim Simons Sold Out
Mario Gabelli 30,000 sh (-1.64%)
Ken Fisher 51,050 sh (-5.2%)
» More
Q2 2014

COO Guru Trades in Q2 2014

Manning & Napier Advisors, Inc 116,400 sh (+19.74%)
Ken Fisher 49,609 sh (-2.82%)
» More
» Details

Insider Trades

Latest Guru Trades with COO

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2014-03-31 New Buy0.14%$117.3 - $138.58 $ 160.4525%245624
Ray Dalio 2012-12-31 Sold Out 0.02%$89.4 - $100.67 $ 160.4568%0
Steve Mandel 2012-09-30 Sold Out 0.95%$72.45 - $94.83 $ 160.4596%0
Ray Dalio 2012-09-30 New Buy0.02%$72.45 - $94.83 $ 160.4596%14658
Steve Mandel 2012-06-30 New Buy0.95%$76.63 - $88.45 $ 160.4592%2017657
Richard Perry 2012-03-31 Sold Out 0.44%$68.74 - $81.96 $ 160.45129%0
Joel Greenblatt 2012-03-31 Sold Out 0.04%$68.74 - $81.96 $ 160.45129%0
Mario Gabelli 2012-03-31 Reduce -25.25%0.01%$68.74 - $81.96 $ 160.45129%75500
Richard Perry 2011-12-31 New Buy0.44%$56.64 - $78.59 $ 160.45139%100000
Ray Dalio 2011-12-31 Sold Out 0.13%$56.64 - $78.59 $ 160.45139%0
Joel Greenblatt 2011-12-31 New Buy0.04%$56.64 - $78.59 $ 160.45139%4189
Ray Dalio 2011-09-30 Add 38.62%0.04%$63.8 - $83 $ 160.45112%108244
Joel Greenblatt 2011-06-30 Sold Out 0.18%$69.16 - $77.5 $ 160.45117%0
John Paulson 2011-06-30 Sold Out 0.05%$69.16 - $77.5 $ 160.45117%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 26.70
COO's P/E(ttm) is ranked higher than
80% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 35.10 vs. COO: 26.70 )
COO' s 10-Year P/E(ttm) Range
Min: 7.98   Max: 1011.75
Current: 26.7

7.98
1011.75
P/B 3.00
COO's P/B is ranked higher than
70% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. COO: 3.00 )
COO' s 10-Year P/B Range
Min: 0.37   Max: 4.45
Current: 3

0.37
4.45
P/S 4.80
COO's P/S is ranked higher than
61% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.89 vs. COO: 4.80 )
COO' s 10-Year P/S Range
Min: 0.51   Max: 5.98
Current: 4.8

0.51
5.98
PFCF 37.10
COO's PFCF is ranked higher than
81% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 83.00 vs. COO: 37.10 )
COO' s 10-Year PFCF Range
Min: 7.34   Max: 342.65
Current: 37.1

7.34
342.65
EV-to-EBIT 24.31
COO's EV-to-EBIT is ranked higher than
75% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.19 vs. COO: 24.31 )
COO' s 10-Year EV-to-EBIT Range
Min: 8.2   Max: 68.2
Current: 24.31

8.2
68.2
PEG 3.60
COO's PEG is ranked higher than
83% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 121.00 vs. COO: 3.60 )
COO' s 10-Year PEG Range
Min: 0.49   Max: 31.7
Current: 3.6

0.49
31.7
Shiller P/E 39.40
COO's Shiller P/E is ranked higher than
84% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. COO: 39.40 )
COO' s 10-Year Shiller P/E Range
Min: 6.66   Max: 49.38
Current: 39.4

6.66
49.38
Current Ratio 2.89
COO's Current Ratio is ranked higher than
75% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.79 vs. COO: 2.89 )
COO' s 10-Year Current Ratio Range
Min: 0.97   Max: 3.46
Current: 2.89

0.97
3.46
Quick Ratio 1.58
COO's Quick Ratio is ranked higher than
67% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. COO: 1.58 )
COO' s 10-Year Quick Ratio Range
Min: 0.69   Max: 2.95
Current: 1.58

0.69
2.95

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 8.00
COO's Price/Tangible Book is ranked higher than
66% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.06 vs. COO: 8.00 )
COO' s 10-Year Price/Tangible Book Range
Min: 3.32   Max: 1473.33
Current: 8

3.32
1473.33
Price/DCF (Projected) 1.70
COO's Price/DCF (Projected) is ranked higher than
85% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.03 vs. COO: 1.70 )
COO' s 10-Year Price/DCF (Projected) Range
Min: 0.55   Max: 5.86
Current: 1.7

0.55
5.86
Price/Median PS Value 1.70
COO's Price/Median PS Value is ranked higher than
59% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.11 vs. COO: 1.70 )
COO' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 2.58
Current: 1.7

0.21
2.58
Price/Peter Lynch Fair Value 1.70
COO's Price/Peter Lynch Fair Value is ranked higher than
94% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. COO: 1.70 )
COO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.6   Max: 70
Current: 1.7

0.6
70
Price/Graham Number 3.00
COO's Price/Graham Number is ranked higher than
78% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.73 vs. COO: 3.00 )
COO' s 10-Year Price/Graham Number Range
Min: 0.77   Max: 49.66
Current: 3

0.77
49.66
Earnings Yield (Greenblatt) 4.10
COO's Earnings Yield (Greenblatt) is ranked higher than
63% of the 252 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.20 vs. COO: 4.10 )
COO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.5   Max: 12.2
Current: 4.1

1.5
12.2
Forward Rate of Return (Yacktman) 17.97
COO's Forward Rate of Return (Yacktman) is ranked higher than
91% of the 260 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.95 vs. COO: 17.97 )
COO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.4   Max: 40.7
Current: 17.97

-1.4
40.7

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, ISRG » details
Traded in other countries:CP6.Germany
Cooper Companies is a Delaware corporation organized in 1980. The Company is a medical device company. The Company operates through two business units: CooperVision, Inc. and CooperSurgical, Inc. They compete on the basis of product quality and differentiation, technological benefit, service and reliability. CooperVision is engaged in the manufacture and sale of products for contact lens wearers. CooperVision develops, manufactures and markets monthly, two-week and single-use contact lenses, including advanced materials and optics. The contact lens market has two major product categories: Spherical lenses including lenses that correct near- and farsightedness uncomplicated by more complex visual defects; and toric and multifocal lenses including lenses that address more complex visual defects such as astigmatism and presbyopia by adding optical properties of cylinder and axis, which correct for irregularities in the shape of the cornea. CooperVision's products are manufactured at its facilities located in Hampshire, United Kingdom, Juana Diaz, Puerto Rico, and West Henrietta, New York. It uses three different manufacturing processes to produce its lenses: lathing, cast molding and FIPS. CooperVision distributes products from West Henrietta, New York, Fareham, United Kingdom, Liege, Belgium, and other international distribution facilities. CooperSurgical focuses on supplying women's health clinicians with products and treatment options to improve the delivery of healthcare to women. CooperSurgical's offers products to aid clinicians in the management and treatment of commonly seen conditions. CooperSurgical customers are healthcare professionals and institutions providing care to and for women. CooperSurgical products support the point of healthcare delivery in the hospital, clinicians office and fertility clinics. CooperSurgical's manufacturing and distribution facilities are located in Trumbull, Connecticut, Malov, Denmark, Pasadena, California, Stafford, Texas, Golden, Colorado, and Berlin, Germany. The Company owns several manufacturing and research and development facilities, including 205,850 square feet in Hamble, United Kingdom, 49,500 square feet in Scottsville, New York, 63,787 square feet in Malov, Denmark, and 33,630 square feet in Stafford, Texas. The Company's products and medical devices are subject to extensive regulation by the United States Food and Drug Administration in the United States and other regulatory bodies abroad. The Company also owns certain trade secrets, copyrights, know-how and other intellectual property.
» More Articles for COO

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Cooper Companies, Broadcom Corp, Realpage Inc, and Freescale Semiconduct Jul 14 2014 
Baron Funds Comments on The Cooper Companies May 02 2014 
CR Bard Focuses on Small to Medium-Sized Deals Apr 04 2014 
Manning & Napier New Buys of Q1 Apr 19 2013 
The Cooper Companies: Not Eyeing It Yet Nov 27 2012 
The Cooper Companies Inc. (COO) CEO - CSI Nicholas J Pichotta sells 6,602 Shares Jan 11 2011 
The Cooper Companies Inc. (COO) CEO - CSI Nicholas J Pichotta sells 2,650 Shares Dec 13 2010 
The Cooper Companies Inc. (COO) CEO - CSI Nicholas J Pichotta sells 9,684 Shares Apr 13 2010 
The Cooper Companies Inc. (COO) CEO - CSI Nicholas J Pichotta sells 15,348 Shares Oct 13 2009 
The Cooper Companies Inc. (COO) CEO Robert S Weiss buys 1,000 Shares Sep 09 2009 

More From Our Partners
C R Bard Q2 Earnings and Revenues Beat Estimates - Analyst Blog Jul 25 2014 - ZACKS

More From Other Websites
NYSE stocks posting largest percentage increases Jul 29 2014
COOPER COMPANIES INC Files SEC form 8-K, Amendment or Waiver to Code of Ethics, Financial Statements... Jul 25 2014
New Lifetime High For Cooper Companies (COO) Jul 22 2014
The Cooper Companies Declares Cash Dividend Jul 10 2014
The Cooper Companies Declares Cash Dividend Jul 10 2014
The Cooper Companies Upped to Buy Jul 07 2014
Why Cooper Companies (COO) Stock Is Falling Today Jul 03 2014
GoPro, Best Buy, Cooper are stocks to watch Jul 03 2014
Cooper Companies - What To Look For After The $1.2 Billion Sauflon Deal Jul 02 2014
The Cooper Companies (COO) Jumps: Stock Rises 8.4% Jul 02 2014
COOPER COMPANIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jul 01 2014
Cooper Companies Acquires Contact Lens Maker Jul 01 2014
Why Cooper Companies (COO) Stock Is Up Today Jul 01 2014
Trade-Ideas: Cooper Companies (COO) Is Today's "Barbarian At The Gate" Stock Jul 01 2014
Stocks to Watch: Twitter, Netflix, Cooper Jul 01 2014
Cooper Companies acquisition has several positive aspects, says Stifel Jul 01 2014
The Cooper Companies Announces Definitive Agreements to Acquire Sauflon Pharmaceuticals Ltd Jun 30 2014
[$$] Cooper Cos. to Buy Contact-Lens Maker Jun 30 2014
Cooper Companies to buy contact lens-maker Sauflon Pharma for $1.2 bln Jun 30 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide